CNBC Television Dr. Anthony Fauci: AstraZeneca’s press release on vaccine data not quite accurate

🎯 Загружено автоматически через бота: 🚫 Оригинал видео: 📺 Данное видео принадлежит каналу «CNBC Television» (@CNBCtelevision). Оно представлено в нашем сообществе исключительно в информационных, научных, образовательных или культурных целях. Наше сообщество не утверждает никаких прав на данное видео. Пожалуйста, поддержите автора, посетив его оригинальный канал. ✉️ Если у вас есть претензии к авторским правам на данное видео, пожалуйста, свяжитесь с нами по почте support@, и мы немедленно удалим его. 📃 Оригинальное описание: White House Chief Medical Advisor Dr. Anthony Fauci said Tuesday morning he had concerns about AstraZeneca’s press release regarding the accuracy of the company’s latest vaccine data. CNBC’s Meg Tirrell reports. For access to live and exclusive video from CNBC subscribe to CNBC PRO: A U.S. health agency said Tuesday that AstraZeneca may have included outdated information in trial results of its Covid-19 vaccine, potentially casting doubt over published efficacy rates. The announcement came just one day after the findings of a large U.S. trial showed that the vaccine was safe and highly effective and throws into question whether AstraZeneca can seek U.S. clearance for the vaccine next month as planned. The Data Safety Monitoring Board “expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data,” the U.S. National Institute of Allergy and Infectious Diseases said in a statement. “We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.” The NIAID said it was notified of the concerns late Monday, along with AstraZeneca and the Biomedical Advanced Research and Development Authority. Led by White House chief medical advisor Dr. Anthony Fauci, the NIAID is part of the National Institutes of Health. Fauci told ABC News’ “Good Morning America” on Tuesday that the Oxford-AstraZeneca shot is “likely a very good vaccine.” However, he added, the DSMB became concerned that the data in AstraZeneca’s public statement “were somewhat outdated and might, in fact, be misleading a bit.” In response, AstraZeneca said that the figures published Monday “were based on a pre-specified interim analysis with a data cut-off of 17 February.” “We will immediately engage with the independent data safety monitoring board (DSMB) to share our primary analysis with the most up to date efficacy data. We intend to issue results of the primary analysis within 48 hours,” the company said in a statement. Shares of AstraZeneca slipped nearly 1% during Tuesday trading in London and were down 2% in premarket trading in New York. U.S. trial results showed that the coronavirus vaccine developed by AstraZeneca and the University of Oxford is 79% effective in preventing symptomatic illness and 100% effective against severe disease and hospitalization. The findings were welcomed as “surprisingly positive” and “good news for the global community.” It was thought the trial data could help to bolster public confidence after a flurry of countries had temporarily suspended their use of the vaccine amid safety concerns. » Subscribe to CNBC TV: » Subscribe to CNBC: » Subscribe to CNBC Classic: Turn to CNBC TV for the latest stock market news and analysis. From market futures to live price updates CNBC is the leader in business news worldwide. The News with Shepard Smith is CNBC’s daily news podcast providing deep, non-partisan coverage and perspective on the day’s most important stories. Available to listen by 8:30pm ET / 5:30pm PT daily beginning September 30: Connect with CNBC News Online Get the latest news: Follow CNBC on LinkedIn: Follow CNBC News on Facebook: Follow CNBC News on Twitter: Follow CNBC News on Instagram: #CNBC #CNBCTV